At what stage is this treatment used?
- Bevacizumab (Avastin®) is an antibody drug that binds to and neutralizes a protein called VEGF-A. It is effective as first-line treatment for mCRC and is used in combination with chemotherapy. The drug is also approved as part of second line treatment in combination with chemotherapy. Patients receive bevacizumab as an intravenous infusion every two weeks and can be scheduled on the same day that chemotherapy is given. Patients may continue bevacizumab even after stopping chemotherapy, as long as the disease is controlled and side effects are manageable.
Is this drug available via the Pharmaceutical Benefits Scheme (PBS) as a subsidised treatment?
- Bevacizumab is PBS-subsidised as a treatment option in combination with first-line chemotherapy (i.e. first-line treatment option), of a patient with previously untreated metastatic bowel cancer with a WHO performance status of 0 or 1.
- Bevacizumab is PBS-subsidised as a treatment option in combination with second-line chemotherapy, of a patient with RAS wild-type metastatic bowel cancer with a WHO performance of 0 or 1, who have been previously treated with PBS-subsidised first-line anti-EGFR antibodies.
Download the Consumer Medicine Information (CMI) for Bevacizumab